CHMP recommends marketing of biologic for atopic dermatitis.

The article reports on the marketing authorization recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for lebrikizumab, an investigational monoclonal antibody that binds to cytokine interleukin-13, for the treatment of adult and adolescent patients with moderate to severe atopic dermatitis who are candidates for systemic therapy. An overview of studies on lebrikizumab as monotherapy and in combination with topical corticosteroids is provided.